NovaBay Pharmaceuticals Unveils Refreshed Consumer Branding for Online Sales of Avenova® Antimicrobial Lid & Lash Solution
March 23 2020 - 6:50AM
Business Wire
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) today
unveils a rebrand for non-prescription Avenova, its antimicrobial
lid and lash solution. The comprehensive refresh reinforces the
Company’s strategy of reaching a broader audience through
Avenova.com and Amazon.com.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20200323005181/en/
Avenova Lid & Lash Solution’s new
consumer branding (Photo: Business Wire)
Avenova is the only patented, FDA-cleared formula that uses pure
hypochlorous acid to treat issues like bacterial dry eye,
blepharitis and contact lens intolerance.
“The goal of the rebrand is to make the sophisticated science
behind our product accessible and appealing to the end consumer. It
also reflects influence from the beauty industry as Avenova is not
only about taking care of how you see but also how you're seen,”
said Justin Hall, NovaBay CEO. “We firmly believe that Avenova is
the safest and most effective product available for the topical
treatment of bacterial infections that affect the majority of
patients with chronic dry eye disease. To build on the momentum we
have experienced with Avenova online sales, we are refreshing our
consumer product messaging and packaging. Our reinvigorated
branding is being combined with cost-efficient social media to
entice new customers to try Avenova. Once people try our product,
we are confident that many will become repeat customers.
“Now that prescription-strength Avenova is available directly to
the end consumer without a prescription, we thought it was
important to have the brand clearly convey our core values. A
scientific approach to personal care is reflected in the "Purely
you" and "Return to Life" themes represented in our new
communications. We expect our refreshed branding to be more
attractive to a broader base of consumers who shop online seeking a
gentle yet powerful antimicrobial solution. Our plan is to have the
new packaging available to consumers for online sales within the
next few months, while prescription Avenova sold through pharmacies
will continue to retain the current packaging.”
Please visit Avenova.com to explore the new website and learn
more about Avenova.
About NovaBay Pharmaceuticals, Inc.: Going Beyond
Antibiotics®
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company
focusing on commercializing and developing its non-antibiotic
anti-infective products to address the unmet therapeutic needs of
the global, topical anti-infective market with its two distinct
product categories: the NEUTROX® family of products and the
AGANOCIDE® compounds. The Neutrox family of products includes
AVENOVA® for the eye care market, CELLERX® for the aesthetic
dermatology market NEUTROPHASE® for wound care market.
Forward-Looking Statements
This release contains forward-looking statements that are based
upon management’s current expectations, assumptions, estimates,
projections and beliefs. These statements include, but are not
limited to, statements regarding our current re-branding strategy,
the launch of a new marketing initiative, and the impact any of
these efforts may have on our future financial results. These
statements involve known and unknown risks, uncertainties and other
factors that may cause actual results or achievements to be
materially different and adverse from those expressed in or implied
by the forward-looking statements. Factors that might cause or
contribute to such differences include, but are not limited to,
risks and uncertainties relating to consumer acceptance of our new
branding, and any potential damage to our established goodwill in
the marketplace. Other risks relating to NovaBay’s business,
including risks that could cause results to differ materially from
those projected in the forward-looking statements in this press
release, are detailed in NovaBay’s latest Form 10-Q/K filings with
the Securities and Exchange Commission, especially under the
heading “Risk Factors.” The forward-looking statements in this
release speak only as of this date, and NovaBay disclaims any
intent or obligation to revise or update publicly any
forward-looking statement except as required by law.
Socialize and Stay informed on
NovaBay’s Progress Like us on Facebook Follow us
on Twitter Connect with NovaBay on LinkedIn Visit
NovaBay’s Website
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200323005181/en/
NovaBay Contact Justin Hall CEO and General Counsel
510-899-8800 jhall@novabay.com
Investor Contact LHA Investor Relations Jody Cain
310-691-7100 jcain@lhai.com
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Aug 2024 to Sep 2024
NovaBay Pharmaceuticals (AMEX:NBY)
Historical Stock Chart
From Sep 2023 to Sep 2024